Molecular Basis of Rifampin Resistance in Streptococcus Pneumoniae

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1999 Oct 3

PMID 10508007

Citations 16

Authors

T Padayachee

K P Klugman

Affiliations

Soon will be listed here.

Abstract

Rifampin resistance among South African clinical isolates of Streptococcus pneumoniae was shown to be due to missense mutations within the rpoB gene. Sequence analysis of 24 rifampin-resistant isolates revealed the presence of mutations within cluster I as well as novel mutations in an area designated pneumococcus cluster III. Of the 24 isolates characterized, only 1 resistant isolate did not contain any mutations in the regions sequenced. Either the cluster I or the cluster III mutations separately conferred MICs of 32 to 128 microg/ml. Clinical isolate 55, for which the MIC was 256 microg/ml, was noted to contain 9 of the 10 mutations identified, which included the cluster I and cluster III mutations. As in Escherichia coli, it is possible that cluster I (amino acids 406 to 434) and cluster III (amino acids 523 to 600) of S. pneumoniae interact to form part of the antibiotic binding site, thus accounting for the very high MIC observed for isolate 55. PCR products containing cluster I or cluster III mutations were able to transform rifampin-susceptible S. pneumoniae to resistance. Although many of the isolates studied displayed identical sequences, pulsed-field gel electrophoresis analysis revealed that the isolates were not of clonal origin.

Citing Articles

Emergence of rifampicin-resistant staphylococci on the skin and nose of rifampicin-treated patients with an orthopaedic-device-related infection.

Wallimann A, Achermann Y, Ferris C, Morgenstern M, Clauss M, Stadelmann V J Bone Jt Infect. 2024; 9(4):191-196.

PMID: 39539997 PMC: 11554714. DOI: 10.5194/jbji-9-191-2024.

Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race.

Baran A, Kwiatkowska A, Potocki L Int J Mol Sci. 2023; 24(6).

PMID: 36982857 PMC: 10056106. DOI: 10.3390/ijms24065777.

Microscale insights into pneumococcal antibiotic mutant selection windows.

Sorg R, Veening J Nat Commun. 2015; 6:8773.

PMID: 26514094 PMC: 4632196. DOI: 10.1038/ncomms9773.

Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.

Srivastava A, Degen D, Ebright Y, Ebright R Antimicrob Agents Chemother. 2012; 56(12):6250-5.

PMID: 23006749 PMC: 3497154. DOI: 10.1128/AAC.01060-12.

New species genetic approach to identify strains of mitis group streptococci that are donors of rifampin resistance to Streptococcus pneumoniae.

Ferrandiz M, Ardanuy C, Linares J, Balsalobre L, Garcia M, Campa A Antimicrob Agents Chemother. 2010; 55(1):368-72.

PMID: 21041504 PMC: 3019657. DOI: 10.1128/AAC.00856-10.

References

Heil A, Zillig W . Reconstitution of bacterial DNA-dependent RNA-polymerase from isolated subunits as a tool for the elucidation of the role of the subunits in transcription. FEBS Lett. 1970; 11(3):165-168. DOI: 10.1016/0014-5793(70)80519-1. View

Kapur V, Li L, Iordanescu S, Hamrick M, Wanger A, Kreiswirth B . Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol. 1994; 32(4):1095-8. PMC: 267194. DOI: 10.1128/jcm.32.4.1095-1098.1994. View

Jin D, Gross C . Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol. 1988; 202(1):45-58. DOI: 10.1016/0022-2836(88)90517-7. View

Tomasz A, HOTCHKISS R . REGULATION OF THE TRANSFORMABILITY OF PHEUMOCOCCAL CULTURES BY MACROMOLECULAR CELL PRODUCTS. Proc Natl Acad Sci U S A. 1964; 51:480-7. PMC: 300099. DOI: 10.1073/pnas.51.3.480. View

Enright M, Zawadski P, Pickerill P, Dowson C . Molecular evolution of rifampicin resistance in Streptococcus pneumoniae. Microb Drug Resist. 1998; 4(1):65-70. DOI: 10.1089/mdr.1998.4.65. View

Sande M . The use of rifampin in the treatment of nontuberculous infections: an overview. Rev Infect Dis. 1983; 5 Suppl 3:S399-401. DOI: 10.1093/clinids/5.supplement_3.s399. View

Williams D, Waguespack C, Eisenach K, Crawford J, Portaels F, Salfinger M . Characterization of rifampin-resistance in pathogenic mycobacteria. Antimicrob Agents Chemother. 1994; 38(10):2380-6. PMC: 284748. DOI: 10.1128/AAC.38.10.2380. View

Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T . Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother. 1993; 37(10):2054-8. PMC: 192227. DOI: 10.1128/AAC.37.10.2054. View

Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston M . Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993; 341(8846):647-50. DOI: 10.1016/0140-6736(93)90417-f. View

10.

Kollenda M, Kamp D, HARTMANN G . Mu-induced rifamycin-resistant mutations not located in the rpoB gene of Escherichia coli. Mol Gen Genet. 1986; 204(1):192-4. DOI: 10.1007/BF00330209. View

11.

Bodmer T, Zurcher G, Imboden P, Telenti A . Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 1995; 35(2):345-8. DOI: 10.1093/jac/35.2.345. View

12.

Yazawa K, Mikami Y, Maeda A, Akao M, Morisaki N, Iwasaki S . Inactivation of rifampin by Nocardia brasiliensis. Antimicrob Agents Chemother. 1993; 37(6):1313-7. PMC: 187958. DOI: 10.1128/AAC.37.6.1313. View

13.

Dower W, Miller J, Ragsdale C . High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res. 1988; 16(13):6127-45. PMC: 336852. DOI: 10.1093/nar/16.13.6127. View

14.

Iwakura Y, Ishihama A, Yura T . RNA polymerase mutants of Escherichia coli. Streptolydigin resistance and its relation to rifampicin resistance. Mol Gen Genet. 1973; 121(2):181-96. DOI: 10.1007/BF00277531. View

15.

Andersen S, Dabbs E . Cloning of nocardioform DNA conferring the ability to inactivate rifampicin. FEMS Microbiol Lett. 1991; 63(2-3):247-50. DOI: 10.1016/0378-1097(91)90093-p. View

16.

Lund A, Duch M, Pedersen F . Increased cloning efficiency by temperature-cycle ligation. Nucleic Acids Res. 1996; 24(4):800-1. PMC: 145669. DOI: 10.1093/nar/24.4.800. View

17.

Honore N, Cole S . Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother. 1993; 37(3):414-8. PMC: 187686. DOI: 10.1128/AAC.37.3.414. View

18.

KNUSEL F, Schiess B . Dominance study with rifampicin-resistant mutants of E. coli K 12. Mol Gen Genet. 1970; 108(4):331-7. DOI: 10.1007/BF00267770. View

19.

. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis. 1976; 134(2):201-4. DOI: 10.1093/infdis/134.2.201. View

20.

Schulin T, Wennersten C, Ferraro M, Moellering Jr R, Eliopoulos G . Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother. 1998; 42(6):1520-3. PMC: 105637. DOI: 10.1128/AAC.42.6.1520. View